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Measurement of SCSb-9 in urine in patients with the nephrotic syn-
drome. In passive or active Heymann nephritis (HN) in the rat, the
immune complexes that form in the glomerular subepithelial space
result in complement activation and the urinary (U) excretion of S
protein-membrane attack complex (SC5b-9, MAC). Because of the
similarities between HN in rats and membranous nephropathy (MN) in
humans, it has been suggested that measurement of SC5b-9 in urine
(UMAC) could be useful in assessing the immunologic activity of MN in
patients. The present study was undertaken in normal individuals and in
patients with nephrotic syndrome to determine: I) the conditions of
urine collection and preservation needed for accurate measurement of
UMAC for clinical purposes; and 2) whether UMAC levels are a
sensitive and/or specific test for MN. In studies conducted on urine
specimens from patients with increased UMAC levels, we found that
UMAC in freshly voided urine was stable for at least three hours at
37°C, with or without the addition of the enzyme inhibitors that were
used to stabilize UMAC levels in the studies of HN in the rat. Urine pH,
leukocytes and erythrocytes, over the ranges usually encountered, did
not influence UMAC levels. However, freezing urine at —70°C artifac-
tually raised UMAC levels (1500 550 to 1800 580 SE nglml, P <
0.001 by paired t-test). Normal urine contained low UMAC levels: 80
3 ng/mg urinary creatinine (Ur). By contrast, patients with glomerul-
opathies tended to have elevated UMAC levels: 18 of 38 patients had
levels that ranged from 200 to 20,000 ng/mg Ucr UMAC levels did not
distinguish patients with MN from those with other causes of glomer-
ulopathy. Indeed, the highest UMAC levels were seen in patients with
nephrotic syndrome due to focal glomeruloscierosis or diabetic glomer-
ulosclerosis. In such patients the ratio: urine protein (Upr)/Ur was
correlated with the logarithm of the ratio UMAC/UCr (r = 0.85, P <
0.001). Biopsy specimens of normal kidney showed no staining for
SC5b-9. Patients with diabetic glomerulosclerosis or focal glomerulo-
sclerosis and elevated UMAC levels showed heavy deposits of SC5b-9
in tubular epithelium but little or no SC5b-9 in glomeruli, suggesting that
in these patients UMAC resulted from SC5b-9 formed on tubular
epithelium. Patients with MN and elevated UMAC levels had SC5b-9
deposits in both glomeruli and tubular epithelium, suggesting that in
these patients UMAC resulted from SC5b-9 formed both in glomeruli
and on tubular epithelium. Patients with idiopathic MN who received a
complete course of immunosuppressive treatment had lower UMAC
levels than those who did not: 1.5 1.0 (N = 7) versus 1120 380(N
= 8) ng/mg Ur, P < 0.02 by unpaired t-test, even though substantial
proteinuria (Upr/Ucr 4.9 2.1 mg/mg) was still present in the treated
patients. We conclude that: 1) UMAC is stable over a wide range of
conditions of collection and storage; and 2) there are two mechanisms
for UMAC formation: (a) glomerular immune complex formation, as
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demonstrated in previous studies of HN, and (b) heavy proteinuria
(generally UprJUr > 4.0 mg/mg), that apparently causes complement
activation on renal tubular epithelial cells, as demonstrated in this
study. The fact that heavy proteinuria itself results in increased UMAC
excretion compromises, but may not invalidate the use of UMAC
measurement to monitor the immunologic activity of MN. Longitudinal
studies will be needed to test that hypothesis.
Rat models of passive or active Heymann nephritis (HN)
have shown that SC5b-9 (MAC) is shed in the urine (U) during
active immune complex formation in the glomerular subepithe-
hal space [1—4]. When immune complex formation in the
glomerular subepithelial space ceases, UMAC excretion rapidly
subsides even though proteinuria continues unabated [1—4]. On
this basis, Pruchno and coworkers [41, and others [5], have
suggested that measurement of UMAC might be clinically
useful in assessing the immunologic activity of MN in patients.
UMAC excretion in HN is the result of complement activa-
tion by the immune complexes that form when specific antibod-
ies bind to glycoproteins expressed on glomerular epithelial cell
(GEC) foot processes [1—4]. UMAC is formed when SC5b-9,
inserted in GEC foot processes, is endocytosed by the GEC and
then exocytosed into the urinary space [2]. Increased UMAC
excretion does not occur when subepithelial immune complex
formation occurs as a result of a "planted antigen" (cationic
human IgG) followed by antibody to that antigen (anti-human
IgG) [3]. Increased UMAC excretion also does not occur when
glomerular injury is induced by nephrotoxic (anti-GBM) serum,
subendothelial immune complex formation by concanavalin A
infusion followed by anti-concanavalin IgG, anti-Thy- 1 (anti-
mesangial cell) antibodies, aminonucleoside nephrosis (PAN)
or ablative nephropathy [3]. Finally, increased UMAC excre-
tion does not occur when rats with severe, nonselective pro-
teinuria induced by PAN are infused with SC5b-9 (approximate-
ly 1000 kD) [3]. Thus, on the basis of animal studies, it appears
that increased UMAC excretion is specific for MN, when the
mechanism of subepithelial IC formation is antibody directed at
antigens expressed on GEC foot processes [1—4].
The present study was undertaken in humans to determine
the potential usefulness of UMAC measurement in the assess-
ment of patients with the nephrotic syndrome. The specific
goals of this study were to: 1) clarify the methods of urine
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collection and preservation needed for valid measurement of
UMAC in patients; and 2) obtain preliminary estimates of the
diagnostic sensitivity and specificity of increased UMAC levels
by measuring UMAC in patients with MN and in patients
representative of each of the other major causes of the ne-
phrotic syndrome.
Methods
Patient description
Studies were performed in 54 patients with proteinuria: 27
MN (20 idiopathic, 5 SLE, 1 drug-induced, 1 cancer), 13 focal
glomerular sclerosis, 6 diabetic glomerular sclerosis, 1 amyloi-
dosis, 1 Wegner's granulomatosis, 5 undiagnosed proteinuric
patients and 10 normal subjects. The renal diagnosis was based
on renal biopsy in all patients except for five of the undiagnosed
proteinuric patients and five of the six patients with a diagnosis
of diabetic giomeruloscierosis. In the diabetic patients not
biopsied, the diagnosis of diabetic glomerulosclerosis was
based on the development of nephrotic range proteinuria after
more than 12 years of insulin dependence, and the presence of
diabetic retinopathy. Patients ranged in age from 18 to 76; 26
were female, 28 were male. Normal subjects ranged in age from
30 to 52 years; 10 were males.
Collection of urine and plasma samples
Studies were performed on samples of recently formed urine
from patients known to have increased UMAC levels from
previous testing. To collect recently formed urine, the patients
voided and discarded that specimen. As soon as possible
thereafter (often within 30 mm and always within 60 mm) the
patients voided again; this sample was immediately placed on
wet ice. A portion was removed for routine urinalysis. The
balance was stored at 4°C until used in the protocols discussed
below. All analyses were performed within six hours of collect-
ing the urine specimens. Plasma specimens were taken from
blood samples drawn in EDTA. The plasma samples were
stored at —70°C until analyzed.
Experimental protocols
Effect of enzyme inhibitors on the stability of UMAC levels. To
assess whether the enzyme inhibitors used in the animal studies
(10 mM benzamidine, 10 ms'i e-aminocaproic acid, 20 mM
EDTA, 100 Kallikrein inhibitor u/mi of aprotinin, 0.05% Tween
20, 0.01% NaN3, pH adjusted to 8.6 with TRIS-HCL buffer) Ill
are necessary to stabilize UMAC in humans, the following was
done: 1 ml of enzyme inhibitor or 1 ml of distilled water was
added to 9 ml portions of each urine specimen. The specimens
without enzyme inhibitor were incubated for three hours at
37°C. The specimens with enzyme inhibitor were incubated at
4°C for three hours. UMAC was then measured in both groups.
Effect of urine pH. The alternative pathway of complement
can be activated by amidation of C3 by ammonia [6]. To assess
whether alkalinization of urine by ammonia could alter UMAC
levels, ammonium hydroxide was added in amounts sufficient to
raise urine pH to 9. The specimens were incubated at 37°C for
three hours. UMAC levels were then measured and compared
to portions of the same urine specimen that was similarly
diluted with distilled water but maintained at 4°C until analysis.
In addition, in 32 patients urine pH measurements were made
by dipstick on the fresh urine specimens. In these specimens we
correlated endogenous urine pH with UMAC level.
Effect of urine leukocytes or erythrocytes on UMAC levels.
Leukocytes in urine could affect UMAC levels. For example,
lysozomal enzymes could degrade UMAC, or killed leukocytes
might permit UMAC formation by providing an "activator site"
on which to initiate alternative pathway activation. To assess
whether leukocytes added to urine can alter UMAC levels, a 1:1
mixture of patients' urine (nephrotic syndrome with increased
UMAC) and urine with leukocytes (uncomplicated, untreated
cystitis) was incubated for three hours at 37°C. The control
consisted of the patient urine diluted 1:1 with distilled water and
incubated for three hours at 37°C. In addition, in 32 patients
urine leukocytes per high power field were determined semi-
quantitatively in freshly voided urine samples after centrifuga-
tion. In these specimens we correlated endogenous urine leu-
kocytes per high powered field with UMAC levels.
Erythrocyte enzymes can generate NH3 from appropriate
substrates to activate the alternative complement pathway [7].
To assess for this possible effect of erythrocytes on UMAC
levels we correlated endogenous erythrocytes per high powered
field of centrifuged urine with UMAC leels.
Effect of freezing at —70°C on UMAC levels. To assess
whether a common method of storing biologic specimens might
alter the assay results for UMAC, samples stored at —70°C for
24 to 48 hours were compared to aliquots of the same urine
stored at 4°C for 24 to 48 hours.
All urine specimens collected for the clinical studies de-
scribed below were freshly voided, placed in a refrigerator
within 15 minutes of voiding and, within 24 hours, frozen at
—70°C until analyzed.
Analytical studies
UMAC was measured using ELISA kits prepared by Quidel
Labs. Urine samples were added to wells lined with a mouse
monoclonal antibody to human SCSb-9. After incubating for one
hour the wells were washed five times. Goat polyclonal antibody
to complement components C6 and C7 labeled with horseradish
peroxidase was added to the wells and allowed to incubate for one
hour. The wells were again washed five times and chromogen
added; after 30 minutes the light absorbance at 405 nm was
measured. A standard curve was generated using known amounts
of SC5b-9 provided with the kit.The sample SC5b-9 levels were
taken from the standard curve. Plasma SC5b-9 levels were mea-
sured in the same manner as urine SCSb-9 described above.
Plasma samples were assayed at 1 to 25 dilution. Urine samples
were assayed at the dilutions needed to achieve optimal density
readings between the high and low controls on the standard curve.
Renal biopsies were immunohistochemically stained for C5b-9
using the labeled avidin D immunoperoxidase technique [8].
Four-micron thick sections were crytostat-cut, air-dried onto glass
slides, and fixed in 4°C acetone for ten minutes. Before immuno-
staining, endogenous tissue biotin was blocked with an avidin-
biotin blocking reagent (Blocking kit, Vector Laboratories, Bur-
lingame, California, USA). Subsequently, slides were incubated
with a mouse monoclonal anti-C5b-9 (gift from Dr. A. F. Michael,
University of Minnesota) at a dilution that in preliminary experi-
ments gave optimal staining. Following incubation for 30 minutes,
the slides were washed in TRIS-buffered saline and incubated with
biotinylated, affinity purified, horse antimouse lgG (Vector Labs).
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4°C with inhibitors 37°C no inhibitors
Fig. 1. The effect on UMAC levels of incubation of urine at 37°C for
three hours with no enzyme inhibitors added vs storage at 4°C for three
hours with enzyme inhibitors added. The lines joining the points
indicate the results of UMAC measured from aliquots of the same urine
specimen. The cause of the nephrotic syndrome in these patients was
MN (N = 15) and focal glomeruloscierosis (N = 1).
Slides were washed, incubated with horseradish peroxidase avidin
D (Vector Labs), washed, and developed in 3-amino-9-ethylcar-
bazole (Sigma Chemical Co, St Louis, Missouri, USA) in 3%
hydrogen peroxide in 0.02 mollliter acetate buffer. Tissues were
counterstained with Gill-Ill hematoxylin. The negative control
consisted of substitution of anti-C5b-9 with an irrelevant mouse
monoclonal antibody of the same isotype. All biopsy cases,
sectioned and fixed as described above, were stained for C3 and
C4 using FITC-labeled monospecific antibodies (Daka) in a stan-
dard direct immunofluorescence assay.
All other measurements were performed in the clinical labo-
ratories of The Ohio State University Hospitals.
All results are shown 1 SEM unless otherwise specified.
Statistical tests used are discussed in relationship to the data.
Results
Effect of collection and storage conditions on UMAC levels
Figure 1 shows that addition of enzyme inhibitors to urine is not
needed to stabilize UMAC levels. That is, the UMAC levels
measured in paired urine samples that either received the enzyme
inhibitor and were stored at 4°C for three hours, or were incubated
at 37°C for three hours without inhibitor, were not significantly
different (680 250 vs. 790 280 ng/ml, P > 0.1 by paired t-test).
UMAC levels were also measured in urine specimens main-
tained at 4°C for three hours, but without enzyme inhibitors.
These results were not different from UMAC levels measured in
aliquots of the same urine specimen studied at 4°C, but to which
the enzyme inhibitors were added (data not shown). Thus, there is
no interaction between storage at 4°C and enzyme inhibitors that
affects UMAC levels.
Figure 2 shows that high urine pH induced by addition of
ammonia does not significantly affect UMAC levels (5730
2400 vs. 6080 2600 ng/ml, P > 0.1 by paired t-test). We also
examined the relationship between UMAC levels and pH (range
5 to 8) of the freshly voided urine specimens from 32 patients.
No significant relationship was present (data not shown).
Figure 3 shows that the addition of leukocytes to urine did not
significantly affect UMAC levels (6550 2600 vs. 8900 3900
Control (pH 5-61 pH 9
Fig. 2. Effect on UMAC levels of raising urine pH to 9 by addition of
ammonia. The urine specimens to which the ammonia was added were
incubated at 37°C for three hours. The results were compared to
aliquots of the same urine specimens which were stored at 4°C for three
hours prior to analysis. The other conventions are the same as those
used in Figure 1. The cause of nephrotic syndrome in these patients was
MN (N = 4), focal glomeruloscierosis (N = 3) and diabetic glomerulo-
sclerosis (N = 1).
H—'i
Control
Fig. 3. Effect on UMAC levels of addition of leukocytes to urine. The
source of urine leukocytes were patients with untreated urinary tract
infections and severe pyuria. The urine specimens were diluted 1 to I
with either infected urine or normal saline and incubated for three hours
at 37°C. The conventions are the same as Figure 1. The cause of
nephrotic syndrome in these patients was MN (N = 4), focal glomeru-
loscierosis (N = 2) and diabetic glomerulosclerosis (N = 1).
ng/ml, P> 0.1), although there was a tendency for UMAC levels
to be higher after addition of leukocytes if the baseline UMAC
level was high. However, no significant relationship was seen
between UMAC levels and endogenous leukocytes (range 0 to 10
leukocytes per high power field of centrifuged urine) in freshly
voided urine specimens of 32 patients (data not shown).
We also examined the relationship between UMAC levels
and endogenous urine erythrocytes per high power field of
centrifuged urine (range 0 to >20, but none with gross hema-
tuna) in freshly voided urine specimens from 32 patients. No
significant relationship was present (data not shown).
Figure 4 shows that freezing urine samples at —70°C artifactu-
ally raises UMAC levels compared to paired urine samples that
were stored for the same period of time at 4°C (1500 550 vs. 1800
580 ng/ml, P < 0.01 by paired i-test, N = 18). This effect,
E
0)
04
aD
2000
1000
0
=
40
20
16
12
8
4
0
°0)C(0
40
30
24
18
12
6
0
37°C with
leukocytes
1144 Ogrodowski et a!: SC5b-9 in nephrotic patients
1000
C)
0
U pr/U Cr
Fig. 5. Relationship between proteinuria and UMAC excretion in
normal individuals and in patients with nonimmune complex-mediated
glomerulopathies, Symbols are: (•) normals (N = 10), (A) diabetic
glomeruloscierosis (N 5), (0) focal glomeruloscierosis (N = 10), ()
other (N = 2). The "other" patients are amyloidosis (higher value) and
Wegener's granulomatosis (lower value). (r = 0.85, P < 0.001).
however, is relatively small and it is not likely to affect the clinical
interpretation of UMAC levels, for reasons discussed below.
Clinical studies
Figure 5 shows UMAC/Ucr in relationship to urine protein
(Upr)/Ucr in 10 normal individuals and 15 proteinuric patients
selected on the basis of having a renal biopsy demonstrating
that the mechanism of proteinuria does not involve glomerular
immune complex formation, and in each patient the measure-
ment of UMAC, Ur and U. was done on the same urine
specimen from that patient. As can be seen, normal individuals
have low UMAC levels (80 3) but patients with proteinuria
tend to have increased UMAC levels. As shown in Figure 5, the
logarithm of UMAC is significantly correlated with the magni-
tude of proteinuria. Thus elevated UMAC levels are not diag-
nostic for MN and appear to be related, at least in part, to the
magnitude of the proteinuria.
Figure 6 shows the relationship between UMAC and protein-
Fig. 6. Relationship between proteinuria and UMAC levels in patients
with MN. Symbols are: (•) idiopathic MN treated (N = 7), (0)
idiopathic MN untreated (N 8), (A) SLE MN treated (N = 3), (A)
SLE MN untreated (N = 2), (rO) cancer associated MN (N = 1), (0)
drug (penicillamine)-induced MN (N = I).
uria in patients with treated or untreated MN (idiopathic, SLE,
drug induced and cancer). These patients were all of those with
MN in whom the measurement of UMAC, Ur and U was done
on the same urine specimen from the given patient. Treated MN
patients (idiopathic as SLE) are those who received within the
previous two years a complete course of therapy with prednisone
[91, prednisone + cyclophosphamide [10], or prednisone + chlor-
ambucil [11]. Untreated MN patients (drug induced, cancer, the
remainder of the idiopathic and SLE patients) are those who
received no therapy, less than a complete course of therapy, or the
treatment occurred more than two years ago and heavy protein-
uria (>4.0 g/24 hr) recurred. As can be seen, compared to the
untreated patients (N = 12), the treated patients (N = 10) have
significantly lower UMAC levels (1.0 0.7 vs. 860 280 ng/mg
Ucr, P < 0.01 by unpaired t-test). Proteinuria in the treated
patients was lower than that of the untreated patients but this
difference did not achieve statistical significance (4.9 1.7 vs. 8.2
1.4 mg/mg Ur, P > 0.1 by unpaired t-test, with or without log
transformation of the data). When only the idiopathic MN patients
were considered, the same relationship was observed: UMAC
was significantly less in the treated (N = 7) compared to the
untreated (N = 8) patients (1.5 1.0 vs. 1120 380 mg/mUr, P
<0.02 by unpaired t-test), but proteinuria was not (4.9 2.1 vs.
8.4 1.7 mg/mU, P > 0.1 by unpaired t-test, with or without log
transformation of the data).
Plasma SC5b-9 levels were measured in 18 of the patients with
the nephrotic syndrome and increased UMAC levels. The mean
plasma SC5b-9 value was 93 50 ng/ml. In 14 of 18 patients,
plasma SC5b-9 levels were undetectable when measured at 1 to 25
dilution. There was no correlation between plasma SC5b-9 levels
and UMAC levels (data not shown).
Staining of renal biopsy specimens for SC5b-9
Tissue was available from patients with focal glomeruloscier-
osis with (N 2) or without (N = 1) increased UMAC, diabetic
glomeruloscierosis and increased UMAC (N = 1), idiopathic
MN and increased UMAC/ (N = 4), and one normal individual.
The kidney tissue from the normal individual was negative for
SC5b-9 (not shown). The patient with focal glomerulosclerosis
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Fig. 4. Effect on UMAC levels of freezing urine at —70°C. Control
samples consisted of aliquots of the same urine specimens but main-
tained at 4°C until time of analysis. Analysis for UMAC levels occurred
within 48 hours of collecting the urine samples from 18 patients. The
conventions are the same as those used in Figure 1.
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Fig. 7. Photomicrograph of C5b-9 staining
in a renal biopsy from a patient with focal
segmental glomerulosclerosis and increased
UMAC. There is intense staining within the
proximal tubules and mild staining within
the mesangium of the glomerulus (x 100;
aminoethylcarbazole with hematoxylin
counterstain).
Fig. 8. Photomicrograph of C5b-9 staining
in a renal biopsy from a patient with
idiopathic MN and increased UMAC. There
is intense staining within the proximal
tubules and along the glomerular capillary
basement membranes (x 100;
aminoethylcarbazole with hematoxylin
counterstain).
Discussion
The present study shows that UMAC is a relatively hardy
molecule. Thus, probably it is not necessary to use stringent
methods for collection and preservation of urine in order to
have UMAC levels in voided urine reflect the levels that were
present in vivo. Indeed, the urine samples without enzyme
inhibitors can be maintained at 37°C for at least three hours
without significant change in UMAC levels. This suggests that
when the urine is retained in the bladder for up to three hours,
and low UMAC levels showed only mild SC5b-9 staining in
glomeruli and tubules (not shown). However, all patients with
increased UMAC had obvious SC5b-9 deposits in glomeruli
and/or tubular epithelium. Representative results from these
patients are shown in Figures 7 and 8. As can be seen, the
patient with focal glomerulosclerosis has heavy staining for
SC5b-9 in tubules, but only mild mesangial staining for SC5b-9
in glomeruli. The patient with idiopathic MN has heavy staining
for SC5b-9 in both glomerular basement membranes and prox-
imal tubules.
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UMAC levels are not affected. This observation also suggests
that UMAC is not generated in the bladders of nephrotic
patients, as has been suggested previously [4]. Thus, it appears
not to be necessary to collect recently formed urine in order
that UMAC levels in voided urine reflect the UMAC level that
exists in vivo. Finally, the present study indicates that over the
ranges of urine pH, leukocytes, or erythrocytes usually seen in
voided urine, there is no important effect of these factors on
UMAC levels.
Previous studies of UMAC have used experimental models of
the nephrotic syndrome in the rat, Those studies showed that in
active or passive HN, increased UMAC levels are seen during
the period of active immune complex formation in the glomer-
ular subepithelial space. When active immune complex forma-
tion in the glomerular subepithelial space ceases, UMAC levels
rapidly subside, even though the proteinuria continues una-
bated [1—41. Those observations led to the suggestion that
measurement of UMAC might be useful in monitoring the
immunologic activity of idiopathic MN. However, the present
studies indicate that there is a second mechanism for UMAC
formation: heavy proteinuria. Indeed, the fact that the highest
UMAC levels are seen in patients with massive proteinuria and
no glomerular immune complex formation indicates that pro-
teinuria is a more potent mechanism for UMAC formation than
is the type of glomerular immune complex formation that is
seen in HN.
The present studies suggest that UpiiUcr ratios less than 4.0
are generally not associated with increased UMAC (>200
ng/mg Ur), whereas UPTJUCr ratios greater than 4.0 generally
are associated with increased UMAC levels.
The mechanism of increased UMAC in patients with massive
proteinuria is not clear. However, it cannot be ascribed to an
artifact related to the high protein concentration in the urine
samples. This interpretation seems justified by the fact that high
urine protein concentration does not necessarily result in high
UMAC levels. In addition, plasma has a protein concentration
higher than that of urine but the plasma C5b-9 levels are low,
relative to the urine samples from nephrotic patients. Filtration
of plasma SC5b-9 in nephrotic syndrome also is an unlikely
source of UMAC because SC5b-9 is very large (approximately
1000 kD) and is not filtered detectably by the glomerulus, even
in the nephrotic syndrome [3]. Also, in the present study we
found no relationship between UMAC levels and plasma C5b-9
levels.
The increased UMAC levels associated with heavy protein-
uria appear to be the result of tubular injury caused by heavy
proteinuria in which the injured tubules provide a site for
alternative complement pathway activation. In support of this
hypothesis, previous studies have shown that heavy proteinuria
can cause tubular injury [12—16] and injured renal tubules can
activate the alternative complement pathway [17]. Indeed, even
normal rat proximal tubule brush border is able to activate the
alternative complement pathway when exposed to undiluted
fresh rat serum [181. Evidence that it is the alternative comple-
ment pathway that is responsible for the SC5b-9 deposit in
tubules is provided by previous studies showing that in patients
with non-selective proteinuria, C3 but not Clq or C4 is present
in proximal tubular brush border [121. Thus, it appears that
renal tubular epithelium can be a site for alternative and
terminal complement pathway activation, and serve as a source
of UMAC in patients with nephrotic syndrome and nonselective
proteinuria. Activation of the classical complement pathway by
angiotensin converting enzyme [19], which is strongly ex-
pressed on proximal tubular brush border [201, is also a possible
mechanism for proteinuria-induced UMAC formation. The
variability in the relationship between UMAC levels and pro-
teinuria observed in this study could be explained in part by the
extent to which a given level of proteinuria results in filtration of
complement pathway proteins.
Studies in humans have shown that in nonselective protein-
uria, intact C3 (approximately 200 kD) is filtered at the glomer-
ulus [12]. All other components of the complement system
needed to activate the alternative pathway and form C5b-9 have
a similar or smaller molecular weight. Thus, it is reasonable to
assume that all components necessary for formation of the
C5b-9 complex are present in urine of patients with nonselec-
tive proteinuria.
SC5b-9 formation on renal tubular epithelium was not ob-
served in rats with the nephrotic syndrome [3], as we have
observed in humans with the nephrotic syndrome. The reason
for this difference between nephrotic syndrome in rats versus
humans is not clear. However, in both active and passive HN,
FxlA antibody can be filtered, bind to tubular brush border and
active complement [2 1—23]. Failure to identify CSb-9 on rat
tubular brush border in HN could represent sloughing of brush
border into urine. Thus, if rat tubular brush border is more
readily sloughed compared to that of the human, this could
explain failure to find MAC on tubular brush border in ne-
phrotic HN rats. It is also possible that the glomerular filtration
of alternative pathway complement components in patients
with nephrotic syndrome is greater than that of rats with the
nephrotic syndrome. Alternatively, rat tubular epithelium, al-
though capable of proteinuria-induced complement activation
[18, 241, might be less susceptible to proteinuria-induced injury
and/or complement activation. In any event, the clear differen-
tiation in rats of HN from other causes of nephrotic syndrome,
based on UMAC excretion, is not present in humans with
nephrotic syndrome.
The fact that there are at least two mechanisms for increasing
UMAC excretion in patients complicates, but may not invali-
date, the use of UMAC to determine the immunologic activity
of MN in patients. For example, with effective immunosuppres-
sive treatment of idiopathic MN, increased UMAC from im-
mune complex formation may cease. If at this point the magni-
tude of the proteinuria is such that tubular injury is not induced,
UMAC levels should fall to low levels, even though substantial
proteinuria might still be present. Such a scenario, which has
been reported previously in small numbers of MN patients [5,
25], would indicate that the immunosuppressive treatment has
been successful. The results shown in Figure 6 provide evi-
dence that such a scenario may have taken place in some of our
patients. That is, there are several patients with treated idio-
pathic MN who still show nephrotic range proteinuria (UPIJUCI
> 3.0) but UMAC levels are low (<200 ng/mg Ur), suggesting
that the immunosuppressive therapy has been successful and
that eventually, the proteinuria should remit. In any event,
longitudinal study of patients with idiopathic MN will be needed
to determine whether serial measurement of UMAC provides
clinically useful information. Such a study is currently under-
way in the North American Nephrotic Syndrome (NANS)
Ogrodowski et a!: SC5b-9 in nephrotic patients 1147
Study (Principal Investigator Dr. Daniel Cattran, University of
Toronto), which is a controlled prospective, multicenter study
of cyclosporin A versus placebo in patients with MN or focal
glomerulosclerosis.
The patients in this study with nephrotic syndrome and MN
secondary to SLE, cancer or drug related (penicillamine), had
low UMAC levels relative to that of patients with idiopathic
MN, at comparable levels of proteinuria. This observation is
consistent with the hypothesis that the MN in patients with
SLE, cancer or drug related, might be the result of planted
antigens, whereas idiopathic MN is more likely the result of
immune complexes involving GEC foot process antigens, as in
HN. This hypothesis is consistent with studies in the rat which
show that glomerular subepithelial immune complex formation,
that is, the result of planted antigens does not result in increased
urinary excretion of SC5b-9, whereas the subepithelial immune
complex formation that occurs as a result of immune complexes
involving GEC antigens, does result in increased urinary excre-
tion of SC5b-9 [1—4].
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